What is REVOLADE?
REVOLADE is a thrombopoietin receptor agonist or TPO-RA with a targeted mechanism of action that increases platelet production without compromising the immune system1,2
REVOLADE is a once-daily film-coated tablet (FCT) for the treatment of patients aged 1 year and above with primary immune thrombocytopenia (ITP) lasting 6 months or longer from diagnosis and who are refractory to other treatment (e.g. cortciosteroids, immunoglobulins).1
What can REVOLADE offer your ITP patients?
Choose REVOLADE for your ITP patients with confidence1–8
FCT, film-coated tablet; ITP, immune thrombocytopenia; TPO-RA, thrombopoietin receptor agonist.
*A total of 5541 subjects have been exposed to REVOLADE since the development international birthdate in October of 2004.8
References
-
REVOLADE Summary of Product Characteristics.
-
Kuter D. Int J Hematol. 2013;98:10–23.
-
Wong R, et al. Blood. 2017;130:2527–2536.
-
Cheng G, et al. Lancet. 2011;377:393–402.
-
Bussel J, et al. Br J Haematol. 2013;160:538–546.
-
Bussel J, et al. Lancet. 2015;2:315–325.
-
Grainger J, et al. Lancet. 2015;386:1649–1658.
-
Data on file REVDOFPATIENTYEARS.